A systematic overview of bexagliflozin: A type 2 diabetic drug

Abstract

Brenzavvy, the brand name for bexagliflozin, is an antidiabetic medication used in conjunction of exercise and a healthy diet to improve glycemic control in individuals with type 2 diabetes (T2D). Bexacat is another brand name for a cat with diabetes. It is a dietary inhibitor of the sodium–glucose cotransporter-2 (SGLT2). SGLT2 inhibitors are relatively new glucose-lowering medications that also help people lose weight and lower their blood pressure in addition to having other positive benefits. Bexagliflozin is an oral SGLT2 powerful inhibitor. T2D and essential hypertension are the two conditions for which it is being developed by TheracosBio. It received its initial approval in the USA on January 20, 2023, for use as a complement to diet and exercise to enhance glycemic control in people with T2D. Bexagliflozin should not be used by anyone who is having dialysis, has type 1 diabetes, or has a glomerular filtration rate that is predicted to be lower than 30 mL/min/1.73 m2. In the USA, bexagliflozin is being developed for use in treating essential hypertension. The key developments that led to bexagliflozin's first approval for the treatment of T2D are outlined in this article.